The filing pertains to an amendment and restatement of the equity incentive plan, not a management change.

Entry into a Material Definitive Agreement. Series E Convertible Preferred Stock Financing On October 13, 2025, TAO Synergies Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which it agreed to sell to the Investors in a private placement (the “ Private Placement ”) (i) an aggregate of 11,000 shares of the Company’s newly designated Series E convertible preferred stock, par value…

Unregistered Sales of Equity Securities. The matters described in Section 1.01 of this Current Report on Form 8-K related to the Private Placement are incorporated herein by reference. In connection with the issuance of the Preferred Stock and the Warrants in the Private Placement described in Item 1.01, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder for transactions not inv…

Director — Jonathan Schechter, Dr. Alan Tuchman: Mr. Schechter and Dr. Tuchman resigned from their positions as directors, but Mr. Tuchman will continue to serve as Chief Medical Officer.

The filing pertains to an amendment and restatement of the Company’s Equity Incentive Plan, not a management change.

Chief Medical Officer — Dr. Alan J. Tuchman, M.D.: Dr. Tuchman resigned as CEO but remains with the company in a new role and on the board.

Other Events. On June 24, 2025, the Company announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy and (ii) that BitGo has been selected to provide qualified custody, staking and trading services for the Company’s TAO holdings. BitGo will secure the Company’s digital assets in regulated, insured cold storage with BitGo Trust Company, Inc. and facilitate the Company's planned acquisitions of TAO through its affiliated trading platform…

Unregistered Sales of Equity Securities The matters described in Section 1.01 of this Current Report on Form 8-K related to the Private Placement are incorporated herein by reference. In connection with the issuance of the Preferred Stock and the Warrants in the Private Placement described in Item 1.01, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder for transactions not invo…

Entry into a Material Definitive Agreement. On June 9, 2025, Synaptogenix, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which it agreed to sell to the Investors in a private placement (the “ Private Placement ”) (i) an aggregate of 5,500 shares of the Company’s newly designated Series D convertible preferred stock, par value $0.0001, with a stated value of $1,000 per share (t…

CEO, Director, Chief Science Officer — Dr. Alan J. Tuchman, Dr. Daniel L. Alkon: Both Dr. Alkon and Dr. Tuchman resigned from their roles but continue to work with the company in new capacities.

The company extended Dr. Tuchman's employment and entered into a consulting agreement with Dr. Alkon, both involving changes in compensation.

Changes in Registrant’s Certifying Accountant. Resignation of Independent Registered Public Accounting Firm On September 30, 2024, in conjunction with its exit from providing audit services to publicly traded companies, Morison Cogen LLP (“Morison Cogen”) resigned from its role as independent registered public accounting firm for Synaptogenix, Inc. (the “Company”). Morison Cogen’s reports on the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2023…

Other Events. On September 12, 2024, the Company completed the private placement of the Preferred Shares and warrants to purchase shares of Common Stock for aggregate gross proceeds of $5 million, before deducting fees commissions and expenses, which the Company previously announced in a Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on September 11, 2024.

Entry into a Material Definitive Agreement. On September 10, 2024, Synaptogenix, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which it agreed to sell to the Investors (i) in a registered direct offering an aggregate of 1,793 shares of the Company’s newly-designated Series C convertible preferred stock, par value $0.0001, with a stated value of $1,000 per share (the “ Preferre…

Unregistered Sales of Equity Securities The matters described in Section 1.01 of this Current Report on Form 8-K related to the Private Placement are incorporated herein by reference. In connection with the issuance of the Unregistered Preferred Shares and the Warrants in the Private Placement described in Item 1.01, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder for transac…

Chief Executive Officer — Alan J. Tuchman, M.D.: The extension of Dr. Tuchman's employment term is a routine administrative matter.

The filing is about an amendment to the equity incentive plan, not a management change.

Entry into a Material Definitive Agreement. On October 31, 2023, Synaptogenix, Inc. (the “Company”) entered into a share purchase agreement (the “Purchase Agreement”) with Cannasoul Analytics Ltd. (“Cannasoul”), pursuant to which the Company agreed to purchase from Cannasoul (i) 12,737 shares of Cannasoul’s Series A preferred shares, no par value per share (the “Preferred Shares”), at a price of $44.1550 per Preferred Share and (ii) a convertible preferred note in an aggregate amount of up to…

Chief Executive Officer — Alan J. Tuchman, M.D.: The term of Dr. Tuchman's employment as CEO was extended.

Notice of Delisting of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. (a) On April 24, 2023, Synaptogenix, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days, the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid…

Results of Operations and Financial Condition. On March 7, 2023, Synaptogenix, Inc. issued a press release disclosing, among other things, that it had approximately $37.5 million in cash as of December 31, 2022. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNAPTOGENIX, INC. Date: March 7, 2023 By: /s/ Robert Weinstein Name: Robert Weinstein Titl…

Other Events. On November 21, 2022, the Company completed the private placement of the Preferred Shares and warrants to purchase shares of Common Stock for aggregate gross proceeds of $15 million, before deducting fees commissions and expenses, which the Company previously announced in a Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on November 18, 2022.